Pillar® ONCO/Reveal™ PillarHS Lung Panel
Targets known lung cancer-related genes
Specifically designed for cell-free DNA
Achieve variant detection at <1% VAF with UIDs
>99% coverage uniformity at 0.2x mean
For research use only. Not for use in diagnostic procedures.
|Enrichment chemistry||Multiplex PCR using tiled amplicons|
|Number of pools||1 pool|
|Number of genes/amplicons||17/81|
|Total panel size||8kb|
|Variant types||SNVs, indels|
|Average amplicon size||147bp|
|Recommended DNA input range||15ng to 50ng|
|% on-target aligned reads||93.2% ± 2.9%|
|Coverage uniformity (% targets with >0.2X mean coverage)||99.8% ± 0.7%|
|Total assay time (from DNA to sequencer)||<9-10 hours|
|Sequencing platforms||Illumina® and MGISEQ™|
See the data
Sensitive variant detection
Cell-free reference DNA (Horizon Discovery) was tested at a nominal level of 0.1% and 0.25%. The ONCO/Reveal pillarHS Lung Panel demonstrated high sensitivity down to 0.1% VAF.
Input DNA was comparable to 20ng of actual cell free DNA.
|Gene||Variant||Exon||0.1% (nominal)||0.25% (nominal)||Wild type|
Pillar provides a seamlessly integrated NGS workflow, from panel design to data analysis.
Primer design platform for reliable amplicon specificity
Enrichment chemistry that enables single-tube amplification
Bioinformatic tools that deliver sensitive, robust variant calls